GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Beta

HLTRF (HLS Therapeutics) Beta : 0.61 (As of Dec. 12, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), HLS Therapeutics's Beta is 0.61.


HLS Therapeutics Beta Historical Data

The historical data trend for HLS Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Beta Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.02 1.01 1.03 0.92

HLS Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.20 0.92 0.85 0.63 0.64

Competitive Comparison of HLS Therapeutics's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Beta falls into.



HLS Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


HLS Therapeutics  (OTCPK:HLTRF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


HLS Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.